论文部分内容阅读
目的探讨多发性骨髓瘤患者中肿瘤坏死因子(TNFα)、β_2-微球蛋白(β2-MG)联合检测的临床应用价值。方法本院38例经血液病诊断标准确诊的多发性骨髓瘤(MM)患者,采用放射免疫分析法联合测定其TNFα和β2-MG水平并进行分析,同时随机选取30名健康体检组最为对照者。结果①初诊MM患者(14例)及复发患者(16例)的TNFα和β2-MG水平均显著高于平稳期MM患者和对照组,差异有统计学意义(P<0.01)。②III期MM患者的TNFα和β2-MG水平均显著高于Ⅱ期患者,Ⅱ期患者又显著高于Ⅰ期患者,差异均有统计学意义(P<0.01);IIIb期MM患者的TNFα水平显著高于IIIa期,差异有统计学意义(P<0.01),而β2-MG水平无统计学差异(P>0.05);Ⅱb期MM患者的β2-MG水平显著高于Ⅱa期,差异有统计学意义(P<0.01),而TNFα水平无统计学差异(P>0.05)。结论TNFα和β2-MG联合检测是MM临床分期、预后及疗效判断的有效指标,能指导临床开展有效的诊疗工作。
Objective To investigate the clinical value of combined detection of tumor necrosis factor (TNFα) and β_2-microglobulin (β2-MG) in patients with multiple myeloma. Methods Thirty-eight patients with multiple myeloma (MM) diagnosed by hematological disease were selected and analyzed by radioimmunoassay. The levels of TNFα and β2-MG in the patients were analyzed. At the same time, 30 healthy people were selected as the most control group . Results ① The levels of TNFα and β2-MG in newly diagnosed MM patients (14 cases) and recurrent patients (16 cases) were significantly higher than those in stable MM patients and controls (P <0.01). ② The levels of TNFα and β2-MG in patients with stage III MM were significantly higher than those in stage II patients, and those in stage II patients were significantly higher than those in stage Ⅰ patients (P <0.01). The levels of TNFα in stage IIIb MM patients were significantly The level of β2-MG in stage Ⅱb MM patients was significantly higher than that in stage Ⅱa stage (P <0.01), while the level of β2-MG was no significant difference (P> 0.05) (P <0.01), while the level of TNFα was not significantly different (P> 0.05). Conclusion The combined detection of TNFα and β2-MG is an effective indicator of the clinical stage, prognosis and curative effect of MM, which can guide clinical diagnosis and treatment work.